Pomegranate: The Savier of Ovarian Cancer

Ovarian cancer is the fifth most common cause of death for women overall and the leading cause of death for women diagnosed with gynecological cancers. The majority of cases are diagnosed at an advanced stage, which results in poor outcomes for this disease. The key early detection strategies include transvaginal ultrasound, a laboratory marker such as the cancer antigen-125 assay, and a detailed gynecological evaluation; however, anti-angio genic bevacizumab and Poly (ADP-ribose) polymerase (PARP) inhibitors have gained traction in the management of this gynecological malignancy in the last ten years. After the initial treatment, a high rate of recurrence has been noted. The majority of these relapsed cases are known to have a higher rate of treatment failures and are less treatable. Therefore, there is an urgent need for innovative treatment methods based on a deeper understanding of the molecular characteristics of this malignancy as well as efficient preventive and detection strategies. In addition to reviewing the epidemiology and risk factors of ovarian cancer, this article discusses some recent ongoing studies and emphasizes the evaluation and multidisciplinary approach in the care of this condition.